Fifteen Korean Drug Firms Granted Innovative Status Charged With Unfair Trade Practices
This article was originally published in PharmAsia News
Executive Summary
Old habits seem to die hard as 15 Korean pharma companies among 43 granted tax breaks and financial incentives to compete at home and abroad are charged with unfair trade practices, including making rebate payments to secure orders.